NEWS
Saint Peter’s University Hospital Offers Next-Generation AI-Powered Therapy to Treat Enlarged Prostate or Benign Prostatic Hyperplasia (BPH)
February 18, 2026
New Brunswick, N.J. – February 18, 2026 — Saint Peter’s University Hospital, a member of Saint Peter’s Healthcare System, is now offering Aquablation® therapy via the HYDROS™ Robotic System, the next-generation procedure to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Relief for BPH is now state of the art, delivered by an AI-powered robotic system. The prior treatment to BPH was surgery that often negatively impacted sexual function and continence, but due to advances in technology, Aquablation can now deliver significant and durable symptom relief.
For millions of men, BPH is an unfortunate reality of aging and impacts urinary function, making it difficult to urinate and fully empty the bladder. Common indicators are the need to urinate frequently, often urgently and an increased need to urinate at night. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones and incontinence. One in two men ages 51-60 have BPH1 and 99 percent of men say BPH impacts their quality of life2.
“Aquablation® is a minimally-invasive surgical option that uses real-time imaging, and an artificial intelligence robotic system called HYDROS™. It uses heat-free waterjet technology to remove the excess prostate tissue that is causing the blockage,” said Akwasi Boateng, MD, urologist at Saint Peter’s University Hospital. “The HYDROS Robotic System allows the surgeon to tailor treatment to each patient’s anatomy while minimizing total surgery time and the risk of complications.”
Saint Peter’s was recently recognized with the America’s 50 Best Hospitals for Outpatient Prostate Care Award™ (2026) – Superior Clinical Outcomes in Benign Prostatic Hyperplasia Treatment from Healthgrades, a resource for evaluating physicians and hospitals nationwide and honoring top-performing organizations through its annual recognitions.
Aquablation therapy is backed by 5-year clinical data demonstrating significant relief of symptoms. To schedule an Aquablation consultation with one of the urologists offering this procedure at Saint Peter’s, visit saintpetershcs.com/aquablation.
About Saint Peter’s University Hospital
Saint Peter’s University Hospital, a member of Saint Peter’s Healthcare System, is a 478-bed acute-care teaching hospital sponsored by the Roman Catholic Diocese of Metuchen. Saint Peter’s, which received its seventh consecutive designation as a Magnet® hospital for nursing excellence by the American Nurses Credentialing Center in 2025, and its first Magnet with Distinction®, is also a state-designated children’s hospital and regional perinatal center, and a regional specialist in diabetes, gastroenterology, head and neck surgery, oncology, orthopedics, and women’s services. Saint Peter’s is the recipient of the Beacon Award for Excellence from the American Association of Critical-Care Nurses for the adult intensive care unit, neonatal intensive care unit, cardiac progressive care unit and the pediatric intensive care unit. The Children’s Hospital at Saint Peter’s University Hospital provides families with access to a full range of pediatric specialties, including a nationally recognized Level IV Neonatal Intensive Care Unit, pediatric surgery and orthopedic surgery featuring innovative anterior scoliosis correction. The hospital has the state’s only hospital-based, midwifery-led birth center – the Mary V. O’Shea Birth Center, accredited by the Commission for the Accreditation of Birth Centers. Saint Peter’s is a sponsor of residency programs in obstetrics and gynecology, pediatrics, and internal medicine, and is a major clinical affiliate of Rutgers Biomedical and Health Sciences. Visit saintpetershcs.com or call 732.745.8600.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Its HYDROS™ Robotic System is the next-generation, AI-powered platform for Aquablation® therapy, a BPH treatment clinically proven to deliver significant, durable symptom relief while preserving sexual function and continence in prostates of all shapes and sizes. The Company has developed a significant and growing body of clinical evidence, including numerous clinical studies and peer-reviewed publications, that support the benefits and clinical advantages of Aquablation therapy.
Risk and Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence/perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention.
Rx Only
Please review the Instructions for Use and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.
© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, HYDROS, PROCEPT BioRobotics, and the PROCEPT BioRobotics logo are trademarks and/or registered trademarks of PROCEPT BioRobotics Corporation. ML0636.A
For millions of men, BPH is an unfortunate reality of aging and impacts urinary function, making it difficult to urinate and fully empty the bladder. Common indicators are the need to urinate frequently, often urgently and an increased need to urinate at night. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones and incontinence. One in two men ages 51-60 have BPH1 and 99 percent of men say BPH impacts their quality of life2.
“Aquablation® is a minimally-invasive surgical option that uses real-time imaging, and an artificial intelligence robotic system called HYDROS™. It uses heat-free waterjet technology to remove the excess prostate tissue that is causing the blockage,” said Akwasi Boateng, MD, urologist at Saint Peter’s University Hospital. “The HYDROS Robotic System allows the surgeon to tailor treatment to each patient’s anatomy while minimizing total surgery time and the risk of complications.”
Saint Peter’s was recently recognized with the America’s 50 Best Hospitals for Outpatient Prostate Care Award™ (2026) – Superior Clinical Outcomes in Benign Prostatic Hyperplasia Treatment from Healthgrades, a resource for evaluating physicians and hospitals nationwide and honoring top-performing organizations through its annual recognitions.
Aquablation therapy is backed by 5-year clinical data demonstrating significant relief of symptoms. To schedule an Aquablation consultation with one of the urologists offering this procedure at Saint Peter’s, visit saintpetershcs.com/aquablation.
About Saint Peter’s University Hospital
Saint Peter’s University Hospital, a member of Saint Peter’s Healthcare System, is a 478-bed acute-care teaching hospital sponsored by the Roman Catholic Diocese of Metuchen. Saint Peter’s, which received its seventh consecutive designation as a Magnet® hospital for nursing excellence by the American Nurses Credentialing Center in 2025, and its first Magnet with Distinction®, is also a state-designated children’s hospital and regional perinatal center, and a regional specialist in diabetes, gastroenterology, head and neck surgery, oncology, orthopedics, and women’s services. Saint Peter’s is the recipient of the Beacon Award for Excellence from the American Association of Critical-Care Nurses for the adult intensive care unit, neonatal intensive care unit, cardiac progressive care unit and the pediatric intensive care unit. The Children’s Hospital at Saint Peter’s University Hospital provides families with access to a full range of pediatric specialties, including a nationally recognized Level IV Neonatal Intensive Care Unit, pediatric surgery and orthopedic surgery featuring innovative anterior scoliosis correction. The hospital has the state’s only hospital-based, midwifery-led birth center – the Mary V. O’Shea Birth Center, accredited by the Commission for the Accreditation of Birth Centers. Saint Peter’s is a sponsor of residency programs in obstetrics and gynecology, pediatrics, and internal medicine, and is a major clinical affiliate of Rutgers Biomedical and Health Sciences. Visit saintpetershcs.com or call 732.745.8600.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Its HYDROS™ Robotic System is the next-generation, AI-powered platform for Aquablation® therapy, a BPH treatment clinically proven to deliver significant, durable symptom relief while preserving sexual function and continence in prostates of all shapes and sizes. The Company has developed a significant and growing body of clinical evidence, including numerous clinical studies and peer-reviewed publications, that support the benefits and clinical advantages of Aquablation therapy.
- -Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3).
- -Data on file at PROCEPT BioRobotics.
Risk and Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence/perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention.
Rx Only
Please review the Instructions for Use and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.
© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, HYDROS, PROCEPT BioRobotics, and the PROCEPT BioRobotics logo are trademarks and/or registered trademarks of PROCEPT BioRobotics Corporation. ML0636.A